Biopharma

Photo
11.12.2024 • News

Amgen Plans $1 Billion Manufacturing Expansion in North Carolina

In a move to expand its global biomanufacturing network, US biopharma Amgen is planning to invest $1 billion to build a second drug substance manufacturing facility at its US site in Holy Springs, North Carolina. This brings the company's total planned investment in Holly Springs to more than $1.5 billion, building on its previously announced $550 million commitment.

Photo
23.07.2024 • News

Agilent to Buy Canadian CDMO Biovectra for $925 Million

Santa Clara, CA-based Agilent Technologies has signed a definitive agreement to acquire specialized contract development and manufacturing organization Biovectra from H.I.G. Capital in a move to expand its end-to-end biopharma solutions.

Photo
05.06.2023 • News

3M Ramps Up Biopharma Filtration Capabilities

Science and technology group 3M has announced plans to invest $146 million to expand its biopharma filtration capabilities at manufacturing facilities in Europe. The company did not disclose the facilities’ locations.

Photo
17.05.2023 • News

FTC Seeks to Block Amgen-Horizon Merger

Calling the deal announced late last year an alarming sign for biopharma, the US Federal Trade Commission (FTC) is seeking to block the closing of Amgen’s proposed $28 billion acquisition of Horizon Therapeutics with a temporary restraining order and preliminary injunction.

Photo
11.05.2023 • News

Wacker Buys All of ADL BioPharma from Private Equity

German chemical group Wacker has acquired 100% of ADL Biopharma from private equity investor Kartesia for a price said to exceed €100 million. It now owns the entire 150,000 m2 production site in the northern Spanish city of Léon with fermentation capacity of just under 3,000 cbm (gross volume).

Photo
10.05.2023 • News

Baxter Sells BioPharma to Private Equity

Confirming media reports, Baxter International announced it has agreed to sell its BioPharma Solutions (BPS) business to a private equity consortium of Warburg Pincus and Advent International for $4.25 billion in cash.

Photo
09.05.2023 • News

Private Equity Steps up for Baxter Biopharma

A private equity consortium of Warburg Pincus and Advent International is said to be in advanced talks to acquire medical device maker Baxter International’s biopharma solutions business. The deal could be worth $4 billion or more, news agencies and the newspaper Wall Street Journal reported.

Photo
22.03.2023 • News

Baxter Said to Eye Sale of Biopharma CMO Arm

Plans by US healthcare company Baxter International to shed its biopharma contract business as it streamlines operations after a poor 2022 earnings performance are gradually taking concrete shape.

Photo
15.03.2023 • News

Sanofi Buying Diabetes Specialist Provention Bio

Paris-based French drugmaker Sanofi has agreed to acquire Provention Bio for $25 per share in cash, representing an equity value of about $2.9 billion. The publicly traded US biopharma focuses on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D).

Photo
15.03.2023 • News

Sumitovant Closes Myovant Purchase

US biopharma Sumitovant – a wholly owned subsidiary of Japan’s Sumitomo Pharma – has closed its purchase of the remaining equity in Myovant Sciences, taking full control of the Swiss clinical-stage biopharma for about $1.7 billion. Myovant will now be delisted from the New York Stock Exchange.

Photo
23.02.2023 • News

Solvay Joins Genesis Consortium to Boost Biotech

Solvay’s venture capital fund has joined the Genesis Consortium, a global alliance of venture capital firms and corporations that support startups leveraging biotechnology to promote both human and planetary health.

Photo
25.01.2023 • News

GenScript Raises $224 Million in Fresh Capital

In its third fundraising round in less than two years, Hong Kong-listed globally active CDMO giant GenScript Biotech has netted a fresh $224 million capital injection for its biologics subsidiary ProBio, which was officially launched under that name in 2020.

Photo
17.01.2023 • News

Resilience and Mubadala in Biopharma Venture

US biopharma manufacturing and technology company National Resilience has entered into an agreement with Abu Dhabi investor Mubadala Investment Company to build a manufacturing plant in the United Arab Emirate’s biggest city. This will be the first GMP biopharma facility in the UAE.

Photo
15.08.2022 • News

Sartorius to Acquire Albumedix for £415 Million

Göttingen, Germany-based life science group Sartorius, through its French-listed subgroup Sartorius Stedim Biotech, plans to acquire all shares of Nottingham, England’s Albumedix, a specialist in recombinant albumin-based solutions, for about £415 million.

Photo
19.05.2022 • News

Cytiva Opens Swiss Cell and Gene Therapy Center

Cytiva, the former biopharma activities of General Electric and now part of Danaher, will open a new manufacturing facility in Grens, Switzerland, on May 31. Operations at the existing site in Eysins will continue through 2023, while full production transfers to the Grens site.

11 more articles

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.